Xponance Inc. Has $850,000 Stock Holdings in Masimo Co. (NASDAQ:MASI)

Xponance Inc. trimmed its holdings in shares of Masimo Co. (NASDAQ:MASI) by 26.2% in the second quarter, Holdings Channel.com reports. The firm owned 6,748 shares of the medical equipment provider’s stock after selling 2,392 shares during the quarter. Xponance Inc.’s holdings in Masimo were worth $850,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Fifth Third Bancorp increased its position in shares of Masimo by 16.4% during the second quarter. Fifth Third Bancorp now owns 695 shares of the medical equipment provider’s stock worth $88,000 after acquiring an additional 98 shares in the last quarter. Oak Thistle LLC increased its holdings in Masimo by 5.2% during the 2nd quarter. Oak Thistle LLC now owns 2,079 shares of the medical equipment provider’s stock worth $262,000 after purchasing an additional 103 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Masimo by 75.0% in the 2nd quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock valued at $33,000 after purchasing an additional 111 shares during the period. HHM Wealth Advisors LLC lifted its holdings in shares of Masimo by 25.0% in the second quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock valued at $79,000 after purchasing an additional 125 shares in the last quarter. Finally, Parallel Advisors LLC boosted its position in shares of Masimo by 48.3% during the fourth quarter. Parallel Advisors LLC now owns 445 shares of the medical equipment provider’s stock worth $52,000 after buying an additional 145 shares during the period. 85.96% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a research report on Friday, September 20th. Piper Sandler lifted their price objective on shares of Masimo from $160.00 to $165.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $144.67.

Masimo Stock Up 0.1 %

MASI stock opened at $133.20 on Friday. The company has a market cap of $7.08 billion, a price-to-earnings ratio of 90.61 and a beta of 0.98. Masimo Co. has a twelve month low of $75.22 and a twelve month high of $153.93. The business has a 50 day moving average price of $117.20 and a two-hundred day moving average price of $125.00. The company has a quick ratio of 1.15, a current ratio of 2.09 and a debt-to-equity ratio of 0.55.

Masimo (NASDAQ:MASI) last issued its earnings results on Tuesday, August 6th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.09. Masimo had a net margin of 3.94% and a return on equity of 14.07%. The business had revenue of $496.30 million for the quarter, compared to the consensus estimate of $493.92 million. During the same period in the previous year, the company earned $0.62 earnings per share. The firm’s revenue for the quarter was up 9.0% on a year-over-year basis. Analysts anticipate that Masimo Co. will post 3.87 EPS for the current fiscal year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.